Business
Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology
(TheNewswire) Key Highlights Positive First-in-Human Results: Three-month Group...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Reports Positive Three Month First-in-Human Results, Significantly De-Risking Its Accommodating Intraocular Lens Technology\n(TheNewswire)\n\n\nKey Highlights\n\n\n\n\nPositive\nFirst-in-Human Results: Three-month Group\n1 data met or exceeded expectations for safety, lens delivery, and\nvision performance. \n\n\n\nMajor De-Risking\nMilestone: The study successfully\nvalidated the core technology and cleared the path to the next\nclinical phase. \n\n\n\nLife-Changing Vision\nImprovements: Patients with severe vision\nloss experienced meaningful improvements in everyday vision. \n\n\n\nStrong Forward\nMomentum: Planning for Group 2 surgeries\nis underway, with lens and delivery enhancements already in\ndevelopment. \n\n\n\nHigh Confidence Going\nForward: Management remains fully\nconfident in the Ocumetics accommodating intraocular lens platform\nfollowing these results. \n\n\n\n\nCalgary, Alberta – February 3,\n2026 – TheNewswire -\nOcumetics Technology Corp. (“Ocumetics”\nor the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader\nin next generation ophthalmic technology, today announced positive\nthree-month postoperative results from Group 1 patients in its\nfirst-in-human (FIH) clinical study of the Ocumetics Accommodating\nIntraocular Lens (the “Ocumetics Lens”). The results validate the\nCompany’s core technology and represent a key clinical de-risking\nmilestone as Ocumetics advances toward subsequent study\nphases. \n\n\nThe Group 1 data met or exceeded all predefined\ninternal benchmarks for safety, lens delivery, and foundational\ndistance visual performance - successfully achieving the primary\nobjectives required to progress the clinical program.\n\n\n“These first-in-human results are exactly what we\nwere aiming to demonstrate at this stage: safe implantation, reliable\ndelivery, and strong visual outcomes,” said Dean Burns, President\nand CEO of Ocumetics.  “Following a detailed\nreview of the data with Dr. Raphael Vasquez, our primary surgeon, I\nremain 100% confident in our accommodating intraocular lens\ntechnology. Based on this success, we have initiated planning for\nGroup 2 surgeries.”\n\n\n \n\n\nClinical Validation and Meaningful\nPatient Impact\n\n\nGroup 1 p...